Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
REVB 
Revelation Biosciences Inc (REVB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: REVB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $21.25
1 Year Target Price $21.25
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.24% | Avg. Invested days 8 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.11M USD | Price to earnings Ratio - | 1Y Target Price 21.25 |
Price to earnings Ratio - | 1Y Target Price 21.25 | ||
Volume (30-day avg) 1 | Beta -0.11 | 52 Weeks Range 1.25 - 50.40 | Updated Date 10/17/2025 |
52 Weeks Range 1.25 - 50.40 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 866.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -57.37% | Return on Equity (TTM) -340.81% |
Valuation
Trailing PE - | Forward PE 0.89 | Enterprise Value -1594733 | Price to Sales(TTM) 2.88 |
Enterprise Value -1594733 | Price to Sales(TTM) 2.88 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.02 | Shares Outstanding 2339306 | Shares Floating 1518762 |
Shares Outstanding 2339306 | Shares Floating 1518762 | ||
Percent Insiders 0.66 | Percent Institutions 3.21 |
Upturn AI SWOT
Revelation Biosciences Inc
Company Overview
History and Background
Revelation Biosciences Inc., founded in 2011, is a clinical-stage biopharmaceutical company focused on the development and commercialization of immunomodulatory therapies for the prevention and treatment of disease. They have evolved through multiple phases of preclinical and clinical research.
Core Business Areas
- Respiratory Disease: Development of products targeting respiratory viral infections.
- Inflammatory Disease: Developing therapies to treat inflammatory diseases.
- Infectious Disease: Researching treatments for bacterial and viral infections.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. The organizational structure is typical of a biotech company, with departments focused on research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- REVTx-99a: A topical nasal drop to prevent or treat respiratory viral infections, including influenza. Currently in clinical development. Market share data is not yet available. Competitors include companies developing vaccines and antiviral therapies such as GSK, Pfizer, and Roche.
- REC-39: A potential treatment for acute kidney injury (AKI). Currently in preclinical development. Competitors include companies developing therapies for AKI such as Baxter and Astellas.
- Immune System Assay Platform: A platform with potential applications in various disease areas. Revenue and market share data are not available. Competitors include companies specializing in biomarker discovery and immune profiling such as Adaptive Biotechnologies and Quanterix.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Demand is driven by unmet medical needs and aging populations.
Positioning
Revelation Biosciences is a smaller player focusing on immunomodulation. Its competitive advantage lies in its novel technology platform and specific therapeutic targets.
Total Addressable Market (TAM)
The TAM for respiratory infections, inflammatory diseases, and AKI represents billions of dollars. Revelation Biosciences is positioned to capture a portion of this TAM through successful clinical development and commercialization of its products.
Upturn SWOT Analysis
Strengths
- Novel immunomodulatory technology platform
- Experienced management team
- Potential to address unmet medical needs
- Diverse pipeline of therapeutic candidates
Weaknesses
- Limited financial resources
- Reliance on successful clinical trial outcomes
- Small market capitalization
- Early stage development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline
- Positive clinical trial results
- Increasing demand for immunomodulatory therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- GILD
- MRK
- PFE
- ABBV
Competitive Landscape
Revelation Biosciences is a small player in a highly competitive market dominated by large pharmaceutical companies. It must differentiate itself through innovative technology and strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on successful clinical trials and partnerships.
Future Projections: Future growth depends heavily on positive clinical trial outcomes and regulatory approvals. Analyst estimates vary widely depending on the success of the company's pipeline.
Recent Initiatives: Recent initiatives include advancing REVTx-99a through clinical trials and exploring partnerships for other therapeutic candidates.
Summary
Revelation Biosciences Inc. is a clinical-stage biopharmaceutical company with a novel immunomodulatory technology platform. While it has the potential to address unmet medical needs, it faces significant risks due to limited financial resources and reliance on successful clinical trial outcomes. The company's future depends on positive data and strategic partnerships. Strong leadership and management is key. They need to focus on funding and the cashflow of the company to stay solvent.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings (10-K, 10-Q)
- Press releases
- Analyst reports (where available)
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own research and due diligence. Market data and estimates may not be precise or up-to-date.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revelation Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-11-17 | Chairman & CEO Mr. James M. Rolke | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.revbiosciences.com |
Full time employees 8 | Website https://www.revbiosciences.com | ||
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.